Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SAVA Stock Forecast 2026-2027
$1.08
Current Price
$52.17M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SAVA Price Targets
+640.7%
To High Target of $8.00
+640.7%
To Median Target of $8.00
+640.7%
To Low Target of $8.00
SAVA Price Momentum
-8.5%
1 Week Change
-11.5%
1 Month Change
-51.1%
1 Year Change
-45.5%
Year-to-Date Change
-78.3%
From 52W High of $4.98
+2.8%
From 52W Low of $1.05
📊 TOP ANALYST CALLS
Did SAVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cassava Sciences is one of their latest high-conviction picks.
Latest SAVA Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, SAVA has a bullish consensus with a median price target of $8.00 (ranging from $8.00 to $8.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.08, the median forecast implies a 640.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Elemer Piros at LUCID CAPITAL MARKETS, projecting a 640.7% upside. Conversely, the most conservative target is provided by Elemer Piros at LUCID CAPITAL MARKETS, suggesting a 640.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SAVA Analyst Ratings
1
Buy
0
Hold
0
Sell
SAVA Price Target Range
Low
$8.00
Average
$8.00
High
$8.00
Current: $1.08
Latest SAVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SAVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 6, 2025 | LUCID CAPITAL MARKETS | Elemer Piros | Buy | Initiates | $8.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $2.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $N/A |
| Nov 26, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Downgrade | $116.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $116.00 |
| Oct 8, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Upgrade | $116.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $N/A |
| Aug 8, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Reiterates | $107.00 |
| Jul 19, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $N/A |
| Jul 1, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| Jul 1, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Downgrade | $N/A |
| May 17, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $131.00 |
| Mar 5, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Jul 6, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| May 11, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| May 9, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Mar 6, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Jan 24, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Aug 11, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $44.00 |
Cassava Sciences Inc. (SAVA) Competitors
The following stocks are similar to Cassava Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SAVA
Cassava Sciences
mkt cap
57.49M
Cassava Sciences Inc. (SAVA) Financial Data
Cassava Sciences Inc. has a market capitalization of $52.17M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -85.4%.
Valuation Metrics
Market Cap
$52.17M
Enterprise Value
$-5,116,497
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+203.3%
Current Ratio
2.3x
Debt/Equity
0.0x
ROE
-85.4%
ROA
-24.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cassava Sciences Inc. (SAVA) Business Model
About Cassava Sciences Inc.
What They Do
Develops treatments for central nervous system disorders.
Business Model
Cassava Sciences Inc. focuses on clinical-stage biotechnology, primarily advancing simufilam for tuberous sclerosis complex-related epilepsy. The company generates value through research and development of innovative therapies that address unmet medical needs in neurodegenerative and neurological conditions.
Additional Information
Founded in 1998 and based in Austin, Texas, the company emphasizes a streamlined operation and has a team of experienced professionals in neuroscience and clinical development. Although it previously explored treatments for Alzheimer's disease, it has shifted its focus to epilepsy therapeutics following the discontinuation of its Alzheimer's program.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Mr. Richard Jon Barry
Country
United States
IPO Year
2000
Website
www.filanatx.comCassava Sciences Inc. (SAVA) Latest News & Analysis
Latest News
Quick Summary
Cassava Sciences announced that the U.S. Department of Justice has concluded its investigation into allegations of research misconduct related to its Alzheimer's drug simufilam.
Why It Matters
The DOJ ending its probe removes uncertainty for Cassava Sciences, potentially boosting investor confidence and stock value, as it clears the path for further development of simufilam.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Cassava Sciences, Inc. (NASDAQ: SAVA) has reached a definitive agreement to resolve a consolidated securities class action lawsuit filed in 2021, related to its operations in CNS disorders.
Why It Matters
Cassava Sciences resolving a major securities class action can reduce legal uncertainties, potentially boosting investor confidence and stabilizing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
6 months ago
Quick Summary
Halper Sadeh LLC is investigating possible breaches of fiduciary duty by officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders should act promptly to enforce their rights.
Why It Matters
Potential breaches of fiduciary duty by Cassava Sciences' officers could lead to legal actions, impacting the company's stock value and shareholder rights, creating urgency for investors to act.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cassava Sciences Inc. (NASDAQ: SAVA) has received a formal letter from the FDA concerning its trial for the drug simufilam.
Why It Matters
FDA communications can signal regulatory hurdles or progress, impacting stock performance and investor sentiment regarding Cassava Sciences’ drug development prospects.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Cassava Sciences, Inc. (NASDAQ: SAVA) has appointed Ms. Dawn C. Bir to its Board of Directors, enhancing its leadership as it develops treatments for CNS disorders.
Why It Matters
Dawn C. Bir's appointment to Cassava's Board could signal strategic shifts or enhanced governance, impacting investor confidence and the company's future direction in CNS treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
8 months ago
Quick Summary
Halper Sadeh LLC is investigating potential breaches of fiduciary duties by Cassava Sciences' officers and directors. Shareholders who acquired shares before September 14, 2020, may seek reforms or financial relief.
Why It Matters
Investigations into fiduciary breaches can lead to legal actions that impact stock prices and corporate governance, influencing investor confidence and potential returns for shareholders of Cassava Sciences.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SAVA Stock
What is Cassava Sciences Inc.'s (SAVA) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Cassava Sciences Inc. (SAVA) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $8.00.
Is SAVA stock a good investment in 2027?
According to current analyst ratings, SAVA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SAVA stock?
Wall Street analysts predict SAVA stock could reach $8.00 in the next 12 months. This represents a 640.7% increase from the current price of $1.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cassava Sciences Inc.'s business model?
Cassava Sciences Inc. focuses on clinical-stage biotechnology, primarily advancing simufilam for tuberous sclerosis complex-related epilepsy. The company generates value through research and development of innovative therapies that address unmet medical needs in neurodegenerative and neurological conditions.
What is the highest forecasted price for SAVA Cassava Sciences Inc.?
The highest price target for SAVA is $8.00 from Elemer Piros at LUCID CAPITAL MARKETS, which represents a 640.7% increase from the current price of $1.08.
What is the lowest forecasted price for SAVA Cassava Sciences Inc.?
The lowest price target for SAVA is $8.00 from Elemer Piros at LUCID CAPITAL MARKETS, which represents a 640.7% increase from the current price of $1.08.
What is the overall SAVA consensus from analysts for Cassava Sciences Inc.?
The overall analyst consensus for SAVA is bullish. Out of 6 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are SAVA stock price projections?
Stock price projections, including those for Cassava Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 12:40 AM UTC